Validation of a Diagnostic Tool for Postprandial Hypoglycaemia in Patients After Roux en Y Gastric Bypass Surgery
EDS
European Dumping Study: Validation of a Diagnostic Tool for Postprandial Hypoglycaemia in Patients After Roux en Y Gastric Bypass Surgery
1 other identifier
observational
40
1 country
1
Brief Summary
Roux-en-Y gastric bypass (RYGB) leads to weight reduction but has also some unwanted side effects. A part of this population will develop postprandial reactive hypoglycemia (PPRH). At this moment no validated diagnostic tool exists for PPRH. The aim of this study is to prove an association between the Sigstad´s Score and the lowest postprandial glucose level in patients after RYGB surgery. This is investigated using a liquid mixed meal tolerance test (LMMTT). As a secondary hypothesis, associations between Edinburgh Hypoglycemia Scale (EHS) and postprandial glucose levels are investigated. Furthermore, changes of insulin and GLP-1 levels during the test are analysed. Patient characteristics including co-morbidities are studied as possible influencing parameters. Moreover, a healthy control group is included to validate the results. Finally, a flowchart/diagnostic method will be proposed for diagnosing patients who had a RYBG surgery with symptoms suggestive of PPRH. Besides the LMMTT, participants at the Ghent University Hospital will undergo additional tests such as a solid mixed meal tolerance test (SMMTT) and continuous glucose monitoring (CGM). Associations between Sigstad Score, EHS and the lowest glucose measured during CGM and SMMTT will be investigated and compared to the results of the LMMTT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 12, 2018
CompletedFirst Posted
Study publicly available on registry
January 23, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 5, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 5, 2020
CompletedDecember 1, 2021
November 1, 2021
2.9 years
January 12, 2018
November 30, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Association between Sigstad's score and the lowest postprandial glucose levels
we are investigating whether there is an association between the Sigtad's score and the lowest glucose levels postprandialy
end 2018
Secondary Outcomes (2)
Association between Ediinburgh Hypoglycemia scale and the lowest postprandial glucose levels
end 2018
flow chart for diagnosis of postprandial reactive hypoglyceamia
end 2018
Study Arms (2)
Gastric Bypass Surgery population
liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
Control population
liquid mixed meal tolerance test, solid mixed meal tolerance test, continuous glucose monitoring
Interventions
three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
Eligibility Criteria
In total 100 GBS patients which will be recruited over multiple sites in Germany, Great Britain, Belgium and Denmark. Belgium will be the only site performing the solid mixed meal tolerance test and the continuous glucose monitoring additional to the liquid mixed meal tolerance test. All other sites will only do the liquid mixed meal tolerance test. In total 20 control patients (10 with a BMI 18-25 kg/m² and 10 with a BMI \> 30 kg/m²) will be recruited. These will be recruited in Belgium (Ghent University Hospital) and the patients will undergo a liquid mixed meal tolerance test, a solid mixed meal tolerance test and a continuous glucose monitoring
You may qualify if:
- for GBS group: primary GBS, 1-5 years post surgery
- for control group: 10 subjects BMI 18-25kg/m² and 10 subjects BMI \>30 kg/m²
You may not qualify if:
- Antidiabetic medication (oral or injectable), somatostatin analogs
- Use of systemic corticosteroids
- for GBS group: Any surgery after RYGB affecting anatomic integrity of the bypass, e.g. banding, conversion of the proximal and/or distal anastomosis
- for GBS group: Any surgery before RYGB affecting anatomic integrity of the bypass, e.g. banding, conversion of the proximal and/or distal anastomosis, sleeve gastrectomy
- Known renal insufficiency: CDK ≥ 4
- Known liver cirrhosis
- Known cardiovascular risk: NYHA ≥ III
- Mental incapacity
- Language barriers with inability to communicate with research staff
- Anemia Hb \< 6.2 mmol/l (10.0 g/dl)
- Cancer within \< 5 years
- Pregnancy
- Allergy to the Fresubin E
- Allergy to components of the solid mixed meal (white bread, cheese spread, margarine, orange)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Ghentlead
Study Sites (1)
Endocrinology, UZ Ghent Hospital
Ghent, 9000, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 12, 2018
First Posted
January 23, 2018
Study Start
June 1, 2017
Primary Completion
May 5, 2020
Study Completion
May 5, 2020
Last Updated
December 1, 2021
Record last verified: 2021-11